Cingulate Inc. (CING) vs XBiotech Inc. (XBIT)

A side-by-side comparison of Cingulate Inc. and XBiotech Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CING

Cingulate Inc.

$67M

$4.98HealthcareDelayed quote: Oct 6, 2026, 2:47 PM EDT

XBIT

XBiotech Inc.

$66M

$2.17HealthcareDelayed quote: Oct 6, 2026, 2:38 PM EDT

Total return — CING vs XBIT

growth of $100 · dividends reinvested · last 5y

CING -99.6% (-66.1%/yr)XBIT -81.1% (-28.3%/yr)XBIT compounded faster over this window

Log scale — wide-divergence pair

CING XBIT

CING vs XBIT: by the numbers

•CING is the larger company ($67M vs $66M market cap).

Metrics side by side

Valuation

Metric	CING	XBIT
P/B ratio	2.86	0.52
EV / EBITDA	0.23	N/A

Profitability

Metric	CING	XBIT
Gross margin	0.00%	0.00%
Operating margin	0.00%	0.00%
Net margin	0.00%	0.00%
ROE	-122.71%	-35.13%
ROIC	-83.74%	-37.01%

Growth (annualized)

Metric	CING	XBIT
Total return CAGR (5Y)	N/A	-29.36%

Go deeper

Full CING analysis Full XBIT analysis Interactive comparison tool

Dig into the metrics

Cingulate ROE XBiotech ROE Cingulate operating margin XBiotech operating margin Cingulate revenue growth XBiotech revenue growth Cingulate free cash flow XBiotech free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.